(Q36285982)

13 August 2017

1 reference

title

Glutamate modulators as novel interventions for mood disorders (English)

1 reference

13 August 2017

Sanjay J Mathew

1

1 reference

13 August 2017

Kathryn Keegan

series ordinal

2

1 reference

13 August 2017

Lisa Smith

series ordinal

3

1 reference

13 August 2017

publication date

1 September 2005

1 reference

Brazilian Journal of Psychiatry

13 August 2017

published in

1 reference

13 August 2017

volume

27

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

243-248

1 reference

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

The cellular neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Volumetric brain imaging findings in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Distinct components of spatial learning revealed by prior training and NMDA receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Phenylglycine derivatives as antagonists of metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Glutamate and depression: clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Clinical studies implementing glutamate neurotransmission in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle--effective hemisphere depends on the behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Riluzole, a glutamate release inhibitor, and motor behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Effects of riluzole on rat cortical neurones: an in vitro electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Effects of depolarizing stimuli on calcium homeostasis in cultured rat motoneurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Riluzole Blocks Dopamine Release Evoked by N-methyl-D-aspartate, Kainate, and Veratridine in the Rat Striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Riluzole enhances glutamate uptake in rat astrocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Antidepressant-like actions of an AMPA receptor potentiator (LY392098).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Current perspectives on the development of non-biogenic amine-based antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

AMPA receptor potentiators for the treatment of CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Some effects of piracetam (UCB 6215 nootropyl) on chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Piracetam improves visuomotor and cognitive deficits in early Parkinsonism--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

Enhancement by an ampakine of memory encoding in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462005000300016

10.1590/S1516-44462005000300016

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference